The involvement of neuroinflammation in an animal model of dementia and depression
Gabriel Casagrande Zabot,Eduarda Behenck Medeiros,Bárbara Machado Naspolini Macarini,Bruno Búrigo Peruchi,Gabriela Serafim Keller,Adrielly Vargas Lídio,Amanda Boaventura,Laura Ceolin de Jesus,Gustavo de Bem Silveira,Paulo Cesar Lock Silveira,Beatriz Costa Chede,Gislaine Zilli Réus,Josiane Budni
DOI: https://doi.org/10.1016/j.pnpbp.2024.110999
IF: 5.201
2024-03-29
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Abstract:Alzheimer's disease (AD) and depression are inflammatory pathologies leading to increased inflammatory response and neurotoxicity. Therefore, this study aimed to evaluate the effect of the treatment with fluoxetine and/or galantamine and/or donepezil on the levels of proinflammatory and anti-inflammatory cytokines in a mixed animal model of depression and dementia. Adult male Wistar rats underwent chronic mild stress (CMS) protocol for 40 days were subjected to stereotaxic surgery for intra-hippocampal administration of amyloid-beta (Aꞵ) peptide or artificial cerebrospinal fluid (ACSF) to mimic the dementia animal model. On the 42nd day, animals were treated with water, galantamine, donepezil, and/or fluoxetine, orally for 17 days. On the 57th and 58th days, the Splash and Y-maze tests for behavior analysis were performed. The frontal cortex and hippocampus were used to analyze the tumor necrosis factor alfa (TNF-α), interleukin 1 beta (IL-1ꞵ), IL-6, and IL-10 levels. The results of this study show that animals subjected to CMS and administration of Aꞵ had anhedonia, cognitive impairment, increased TNF-α and IL-1ꞵ levels in the frontal cortex, and reduced IL-10 levels in the hippocampus. All treatment groups were able to reverse the cognitive impairment. Only donepezil did not decrease the TNF-α levels in the hippocampus. Fluoxetine + galantamine and fluoxetine + donepezil reversed the anhedonia. Fluoxetine reversed the anhedonia and IL-1ꞵ levels in the frontal cortex. In addition, fluoxetine + donepezil reversed the reduction of IL-10 levels in the hippocampus. The results indicate a pathophysiological interaction between AD and depression, and the association of medications in the future may be a possible therapeutic strategy to reduce inflammation, especially the fluoxetine-associated treatments.
pharmacology & pharmacy,neurosciences,psychiatry,clinical neurology